AblaCor Medical Corporation
AblaCor is developing a new medical product to significantly reduce the burden of atrial fibrillation, while providing a positive ROI for investors.
AblaCor’s mission is to develop a catheter ablation system that will significantly advance the treatment of atrial fibrillation (AF), the most common irregular heart rhythm. AblaCor’s CircumBlator™ system will enable a procedure that offers a low complication rate, shorter procedure times, and fewer repeat procedures. AblaCor’s competitive advantage is controlled contact with the heart tissue to provide consistent, continuous ablations.